Recent advances in the therapeutic perspectives of nutlin-3

Current Pharmaceutical Design

Volumn 17, Issue 6, 2011, Pages 569-577

  Secchiero, Paola ^a   Bosco, Raffaella ^a   Celeghini, Claudio ^b   Zauli, Giorgio ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

Apoptosis; Hematological malignancies; P53 pathway; Pediatric malignancies; Senescence; Therapeutic combinations

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYTOCHROME C; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMATINIB; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RETINOIC ACID; RG 7112; RO 5045337; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL HYPOXIA; CELL MIGRATION; CHILDHOOD CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; ENDOTHELIUM CELL; HUMAN; IC 50; NEGATIVE FEEDBACK; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RETINOBLASTOMA; RHABDOMYOSARCOMA; TRANSCRIPTION REGULATION; TUMOR CELL;

EID: 79953655080     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795222586     Document Type: Article

References (118)

1. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-8.
2. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005; 5: 3-8.
3. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 2008; 14: 2100-10.
4. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-3.
5. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55: 96-107.
6. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2: 202-6.
7. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13: 49-58.
8. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
9. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
10. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927-34.
11. Francoz S, Froment P, Bogaerts S, et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006; 103: 3232-7.
12. Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma C. Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies. Cell Cycle. 2010; 9 [Epub ahead of print]
13. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006; 66: 3169-76.
14. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006; 281: 33030-5.
15. Dal Bo M, Secchiero P, Degan M, et al. MDM4 (MDMX) is over-expressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. Br J Haematol 2010; 150: 237-9.
16. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008; 7: 1604-12.
17. Bai F, Zhu F, Tagen M, et al. Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Pharm Biomed Anal. 2010; 51: 915-20.
18. Zhang F, Tagen M, Throm S, et al. Whole body physiologically-based pharmacokinetic model for Nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos. 2010 Oct 14. [Epub ahead of print]
19. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61-6.
20. Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol 2006; 124: 1269-75.
21. Shields CL. Forget-me-nots in the care of children with retinoblas-toma. Semin Ophthalmol 2008; 23: 324-34.
22. Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003;197: 93-8.
23. Michaelis M, Rothweiler F, Klassert D, et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009; 69: 416-21.
24. Van Maerken T, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006; 66: 9646-55.
25. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, Shohet JM. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006; 5: 2358-65.
26. Becker K, Marchenko ND, Maurice M, Moll UM. Hyperubiquity-lation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ 2007; 14: 1350-60.
27. Chen L, Malcolm AJ, Wood KM, et al. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007; 6: 2685-96.
28. Peirce SK, Findley HW. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity. Oncol Rep 2009; 22: 1443-9.
29. Van Maerken T, Ferdinande L, Taildeman J, et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 2009; 101:1562-74.
30. Peirce SK, Findley HW. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol 2009; 34: 1395-402.
31. Muth D, Ghazaryan S, Eckerle I, et al. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res 2010; 70: 3791-802.
32. Miyachi M, Kakazu N, Yagyu S, et al. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhab-domyosarcoma cells. Clin Cancer Res 2009; 15: 4077-84.
33. Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leu-kemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008; 22: 730-9.
34. Zhu N, Gu L, Li F, Zhou M. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther 2008; 7: 1101-9.
35. Mitani N, Niwa Y, Okamoto Y. Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem 2007;44:557-9.
36. Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609-17.
37. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-9.
38. Secchiero P, Zerbinati C, di Iasio MG, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway Nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007; 8: 395-403.
39. Zhang W, Konopleva M, Burks JK, et al. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res 2010; 70: 2424-34.
40. Carter BZ, Mak DH, Schober WD, et al. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 2010; 115: 306-14.
41. Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 4122-9.
42. Coll-Mulet L, Iglesias-Serret D, Santidrián AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109-14.
43. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008; 111: 1584-93.
44. Tabe Y, Sebasigari D, Jin L, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 2009; 15: 933-42.
45. Jin L, Tabe Y, Kojima K, et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett 2010; [Epub ahead of print]
46. Abdul-Nabi AM, Yassin ER, Varghese N, Deshmukh H, Yaseen NR. In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. PLoS One 2010; 5: e12464.
47. Long J, Parkin B, Ouillette P, et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010; 116: 71-80.
48. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
49. Zauli G, di Iasio MG, Secchiero P, et al. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. Curr Cancer Drug Targets 2009; 9: 510-8.
50. Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. Clin Cancer Res 2010; 16: 1824-33.
51. Secchiero P, Melloni E, di Iasio MG, et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 2009; 113: 4300-8.
52. Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856-65.
53. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-14.
54. Sohn D, Essmann F, Schulze-Osthoff K, Jänicke RU. p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res 2006; 66: 11254-62.
55. Garner E, Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle 2008; 7: 277-82.
56. Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci 2009; 100: 1128-36.
57. Ferrandiz N, Caraballo JM, Albajar M, et al. p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells. Cancer Lett 2010; 292: 133-9.
58. Xia M, Knezevic D, Vassilev LT. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. Oncogene. 2010 Sep 27. [Epub ahead of print]
59. Kumamoto K, Spillare EA, Fujita K, et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008; 68: 3193-203.
60. Dalgard CL, Gonzalez M, deNiro JE, O'Brien JM. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Invest Ophthalmol Vis Sci 2009; 50: 4542-51.
61. Georges SA, Chau BN, Braun CJ, Zhang X, Dobbelstein M. Cell cycle arrest or apoptosis by p53: are microRNAs-192/215 and -34 making the decision Cell Cycle 2009; 8: 680-1.
62. Braun CJ, Zhang X, Savelyeva I, et al. p53-Responsive microRnas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68: 10094-104.
63. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005; 17: 631-6.
64. Steele AJ, Prentice AG, Hoffbrand AV, et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood 2008; 112: 3827-34.
65. Vaseva AV, Marchenko ND, Moll UM. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle 2009; 8: 1711-9.
66. Saha MN, Jiang H, Chang H. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: Evidence for p53-transcription-dependent and -independent pathways. Cancer Biol Ther 2010; 10 [Epub ahead of print]
67. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007; 26: 3473-81.
68. Secchiero P, Zerbinati C, Melloni E, et al. The MDM-2 antagonist Nutlin-3 promotes maturation of acute myeloid leukemic blasts. Neoplasia 2007; 9: 853-61.
69. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008; 13: 11-22.
70. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S. Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 1996; 271: 22961-22964.
71. Gibellini D, Bassini A, Pierpaoli S, et al. Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 1998; 160: 3891-8.
72. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008; 27: 5303-14.
73. Huart AS, MacLaine NJ, Meek DW, Hupp TR. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem 2009; 284: 32384-94.
74. Peirce SK, Findley HW. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol 2009; 34: 1395-402.
75. Ray RM, Bhattacharya S, Johnson LR. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 2010; [Epub ahead of print]
76. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2007; 27: 997-1003.
77. Cipriano R, Patton JT, Mayo LD, Jackson MW. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed pheno-type that remains susceptible to nutlin-3 mediated apoptosis. Cell Cycle 2010; 9 [Epub ahead of print]
78. Cheok CF, Kua N, Kaldis P, Lane DP. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ 2010; 17: 1486-500.
79. Secchiero P, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008; 15: 42-8.
80. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331-40.
81. Drakos E, Atsaves V, Schlette E, et al. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lym-phoma with wild-type or mutated p53. Leukemia 2009; 23: 2290-9.
82. Hasegawa H, Yamada Y, Iha H, et al. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senes-cence in adult T-cell leukemia cells. Leukemia 2009; 23: 2090-101.
83. Hori T, Kondo T, Kanamori M, et al. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett 2010; 287: 98-10.
84. Zamai L, Secchiero P, Pierpaoli S, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000; 95: 3716-24.
85. Campioni D, Secchiero P, Corallini F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005; 166: 557-63.
86. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28: 2839-46.
87. Secchiero P, Corallini F, Rimondi E, et al. Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood 2008; 111: 1287-94.
88. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009; 66: 841-851.
89. Zauli G, Corallini F, Bossi F, et al. Osteoprotegerin increases leu-kocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110: 536-43.
90. Ooi MG, Hayden PJ, Kotoula V, et al. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 2009; 15: 7153-60.
91. Thompson T, Andreeff M, Studzinski GP, Vassilev LT. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Mol Cancer Ther 2010;9: 1158-68.
92. Zhang L, Yan Y, Zhu D, et al. Nutlin-1 strengthened antiproliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells. Invest New Drugs 2010; [Epub ahead of print]
93. Palani CD, Beck JF, Sonnemann J. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Invest New Drugs 2010; [Epub ahead of print]
94. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 2010; 9: 936-44.
95. Voltan R, Celeghini C, Melloni E, Secchiero P, Zauli G. Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity. Br J Haematol 2010; 148: 957-61.
96. Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis 2010; 15: 608-20.
97. Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res 2007; 67: 7350-7.
98. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-60.
99. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-5.
100. O'Callaghan-Sunol C, Gabai VL, Sherman MY. Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res 2007; 67: 11779-88.
101. Huang B, Vassilev LT. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3. Aging 2009; 1: 845-54.
102. Arya AK, El-Fert A, Devling T, et al. Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br J Cancer 2010; 103: 186-95.
103. Shen H, Maki CG. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem 2010; 285: 23105-14.
104. Korotchkina LG, Demidenko ZN, Gudkov AV, Blagosklonny MV. Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle 2009; 8: 3777-81.
105. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging 2010; 2: 344-52.
106. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107: 9660-4.
107. LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res 2007; 67: 450-4.
108. Lee YM, Lim JH, Chun YS, Moon HE, Lee MK, Huang LE, Park JW. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis 2009; 30: 1768-75.
109. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 2009; 69: 9056-64.
110. Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008; 7: 993-9.
111. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 2010; [Epub ahead of print]
112. Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol 2010; 2: 001057.
113. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol. 2010; 22: 181-5.
114. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of Mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010; 90: 1383-435.
115. Scherz-Shouval R, Weidberg H, Gonen C, Wilder S, Elazar Z, Oren M. p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci USA 2010; 107: 18511-6.
116. Amrein L, Soulières D, Johnston JB, Aloyz R. P53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk Res 2010; [Epub ahead of print]
117. Secchiero P, Corallini F, Gonelli A, et al. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res. 2007; 100: 61-9.
118. Moran DM, Maki CG. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther 2010; 9: 895-905.